Properties (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
naltrexone
|
| gptkbp:availability |
prescription required
|
| gptkbp:brand |
gptkb:Vivitrol
|
| gptkbp:clinicalTrials |
substance use disorder
Phase 3 alcohol use disorder opioid use disorder |
| gptkbp:contraindication |
acute hepatitis
allergic reaction to naltrexone |
| gptkbp:date |
2010-10-01
|
| gptkbp:dosageForm |
solution
|
| gptkbp:drugInterdiction |
opioids
prescription only buprenorphine opioid antagonists methadone |
| gptkbp:evaluates |
reduces cravings
reduces relapse rates |
| gptkbp:formFactor |
injection
|
| gptkbp:hasPopulation |
adults
adolescents |
| gptkbp:healthcare |
avoid opioids during treatment
report any side effects |
| https://www.w3.org/2000/01/rdf-schema#label |
Vivitrol
|
| gptkbp:impact |
monthly
|
| gptkbp:is_monitored_by |
liver function tests
mental health status |
| gptkbp:lastProduced |
gptkb:FDA
|
| gptkbp:launchSite |
once a month
gluteal muscle |
| gptkbp:manufacturer |
Alkermes
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:notableFeature |
Depade
Revia |
| gptkbp:offers |
varies by insurance
approximately $1,000 per injection |
| gptkbp:patentExpiration |
2027-04-01
|
| gptkbp:patentType |
yes
|
| gptkbp:researchInterest |
ongoing
completed |
| gptkbp:route |
intramuscular
|
| gptkbp:sideEffect |
anxiety
fatigue headache nausea insomnia |
| gptkbp:storage |
refrigerated
|
| gptkbp:triggerType |
opioid receptor antagonist
|
| gptkbp:type |
no
|
| gptkbp:usedFor |
alcohol dependence
opioid dependence |